Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01934179 · ClinicalTrials.gov registry record
Telomere Length in Predicting Toxicity in Older Patients With Stage III-IV Colorectal Cancer Undergoing Chemotherapy
A clinical trial, sponsored by Fox Chase Cancer Center.
- Terminated
- Registry status
- 6
- Enrollment target
NCT01934179: Clinical Trial study, sponsored by Fox Chase Cancer Center.
NCT01934179 is a clinical trial that was terminated before completion, run by Fox Chase Cancer Center. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01934179 was terminated before completion, sponsored by Fox Chase Cancer Center.
- TERMINATED
- Registry status
- 6 participants
- Enrollment target
Study Summary
This pilot research trial studies telomere length in predicting toxicity in older patients with stage III-IV colorectal cancer undergoing chemotherapy. Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and predict how well patients will respond to treatment.
Primary Outcome
TL will be compared between participants experiencing at least 1 adverse event and those who experience none using the Mann-Whitney test. A type I error of 5% will be used to determine statistical significance.
Interventions
- OTHER laboratory biomarker analysis
- OTHER cytology specimen collection procedure
- OTHER questionnaire administration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2013-10 |
| Est. Completion | 2015-09-11 |
Why NCT01934179 stopped before completion
NCT01934179 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 6 participants, a relatively small participant target.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT01934179 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01934179 about?
NCT01934179 is a clinical study titled "Telomere Length in Predicting Toxicity in Older Patients With Stage III-IV Colorectal Cancer Undergoing Chemotherapy". This pilot research trial studies telomere length in predicting toxicity in older patients with stage III-IV colorectal cancer undergoing chemotherapy. Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid ...
What is the current status of trial NCT01934179?
This trial is currently terminated. The enrollment target is 6 participants. The study started on 2013-10. Estimated completion is 2015-09-11.
What interventions are being tested in trial NCT01934179?
The interventions under investigation include: laboratory biomarker analysis (OTHER), cytology specimen collection procedure (OTHER), questionnaire administration (OTHER).
Who is sponsoring clinical trial NCT01934179?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia